KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.

Alessandra Rossi, Stefania Orecchioni, Paolo Falvo, Valentina Tabanelli, Elena Baiardi, Claudio Agostinelli, Federica Melle, Giovanna Motta, Angelica Calleri, Stefano Fiori, Chiara Corsini, Beatrice Casadei, Saveria Mazzara, Umberto Vitolo, Francesco Bertolini, Pier Luigi Zinzani, Myriam Alcalay, Pier Giuseppe Pelicci, Stefano Pileri, Corrado Tarella, Enrico Derenzini

Leukemia 36(1) 197-209

PMID34304248
PMCIDPMC8727301
DOI10.1038/s41375-021-01347-6
发表日期2021-07-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

Standard chemotherapies for diffuse large B-cell lymphoma (DLBCL), based on the induction of exogenous DNA damage and oxidative stress, are often less effective in the presence of increased MYC and BCL-2 levels, especially in the case of double hit (DH) lymphomas harboring rearrangements of the MYC and BCL-2 oncogenes, which enrich for a patient's population characterized by refractoriness to anthracycline-based chemotherapy. Here we hypothesized that adaptive mechanisms to MYC-induced replicative and oxidative stress, consisting in DNA damage response (DDR) activation and BCL-2 overexpression, could represent the biologic basis of the poor prognosis and chemoresistance observed in MYC/BCL-2-positive lymphoma. We first integrated targeted gene expression profiling (T-GEP), fluorescence in situ hybridization (FISH) analysis, and characterization of replicative and oxidative stress biomarkers in two independent DLBCL cohorts. The presence of oxidative DNA damage biomarkers identified a poor prognosis double expresser (DE)-DLBCL subset, characterized by relatively higher BCL-2 gene expression levels and enrichment for DH lymphomas. Based on these findings, we tested therapeutic strategies based on combined DDR and BCL-2 inhibition, confirming efficacy and synergistic interactions in in vitro and in vivo DH-DLBCL models. These data provide the rationale for precision-therapy strategies based on combined DDR and BCL-2 inhibition in DH or DE-DLBCL.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。